An experimental malaria vaccine being developed by one of the world’s biggest drug companies has protected small babies for as long as 18 months, getting them through the most vulnerable time, researchers reported Tuesday. GlaxoSmithKline asked the European Medicines Agency last week for approval to market the vaccine, called RTS,S.
Tests on more than 15,000 babies aged 6 weeks to 17 months old showed close to half of them — 46 percent — were protected from malaria for 18 months after they got a three-dose series of the vaccine, Mary Hamel of the U.S. Centers for Disease Control and Prevention and partners reported. The vaccine averted an average of 829 cases of malaria per 1,000 children vaccinated, they reported in the Public Library of Science journal PLoS Medicine. That would have a major impact in a large population, they said. Malaria is a major killer globally. The World Health Organization estimates there are more than 200 million cases of malaria every year and it kills more than 600,000 people, mostly young children.
— Maggie Fox
First published July 29 2014, 2:05 PM
Maggie Fox is senior health writer for NBC News and TODAY, writing top news on health policy, medical treatments and disease.
... Expand Bio
She's a former managing editor for healthcare and technology at National Journal and global health and science editor for Reuters based in Washington, D.C. and London.
She's reported for news agencies, radio, newspapers, magazines and television from across Asia, the Middle East, Africa and Europe covering news ranging from war to politics and, of course, health and science. Her reporting has taken Maggie to Lebanon, Syria and Libya; to China, South Korea, Thailand, the Philippines and Pakistan; to Bosnia, Croatia and Serbia and to Ireland and Northern Ireland and across the rest of Europe.
Maggie has won awards from the Society of Business Editors and Writers, the National Immunization Program, the Overseas Press Club and other organizations. She's done fellowships at Harvard Medical School, the National Institutes of Health and the University of Maryland.